Myelo Therapeutics Expands NIH-NIAID Collaboration and Joins Bayer Pharmaceuticals Incubator

BERLIN, GERMANY, March 3rd, 2021 - Myelo Therapeutics GmbH, a clinical-stage pharmaceutical company focused on developing medical countermeasures (MCM) and therapies for cancer supportive care and, announced today an expansion of the scope and funding of its development contract with the U.S. National Institute of Allergy and Infectious Diseases (NIAID). Under the contract awarded in 2020, Myelo Therapeutics is developing the clinical-stage new chemical entity Myelo001 as an oral formulation MCM for the treatment of Hematopoietic Acute Radiation Syndrome (H-ARS).

The additional funds Myelo Therapeutics GmbH will receive are to investigate the use of Myelo001 as a radiation countermeasure for the pediatric population. The program is funded in whole or in part with U.S. Federal funds from the Radiation and Nuclear Countermeasures Program (RNCP), NIAID, National Institutes of Health (NIH), Department of Health and Human Services (HHS), under Contract No. 75N93020C00005.

Myelo Therapeutics also announced that the company was selected to join the *Bayer CoLaborator,* the Bayer Pharmaceuticals incubator in Berlin. The CoLaborator offers life science companies ready-to-use laboratory infrastructure without strings attached and access to the Bayer's research expertise and infrastructure.

"*We are very happy that with Myelo Therapeutics another innovative company is joining the Bayer CoLaborator*," states Dr. Cora Scholten, Alliance Manager of Bayer AG. "*We now have a total of nine companies based in our incubator in Berlin.*"

Myelo001 is a clinical-stage adjuvant cancer therapy for the treatment of chemotherapy- and radiotherapy-induced myelosuppression. It is delivered as an oral tablet formulation and is stable at room temperature for at least 3 years. Preclinical and clinical studies have shown that Myelo001 has both prophylactic and therapeutic efficacy at reducing hematopoietic symptoms caused by radiation and chemotherapy. In irradiated mice and rabbits, Myelo001 reduced the nadir and accelerated recovery of neutrophils, lymphocytes, thrombocytes, and erythrocytes. In mice, treatment 24 hours post-total body irradiation resulted in increased survival, faster bone marrow recovery, and reduced body weight loss. Moreover, Myelo001 treatment prior and after chemotherapy led to a faster recovery of blood cells in human subjects. Comprehensive chronic toxicology and safety studies, as well as clinical studies, have confirmed Myelo001's excellent safety profile.

About Myelo Therapeutics: Myelo Therapeutics is a pharmaceutical company based in Berlin, Germany, that is developing innovative treatments in areas of high unmet medical needs, such as Chemotherapy-induced Myelosuppression (CIM), Radiation-induced Myelosuppression (RIM), and Acute Radiation Syndrome (ARS). For more information, visit www.myelotherapeutics.com.

Contact: Myelo Therapeutics GmbH, Till Erdmann, Managing Director, Rheinsberger Str. 7, 10115 Berlin, Germany, info@myelotherapeutics.com

The information included in this press release concerns a drug use that has not been approved by the Food and Drug Administration.